The two companies have now entered into exclusive negotiations — DIC’s offer values PCAS Canada at €88.2 million. A final decision would remain subject to authorization from PCAS’ supervisory board and majority shareholder Seqens, along with other conditions, PCAS said.

PCAS Canada specializes in the synthesis, development and custom manufacture of ingredients used in the formulation of light-sensitive resins, anti-reflective products for microelectronics or as semiconductors for the printed electronics industry. The company also manufactures organic molecules used in pharmaceutical production.

Author: Elaine Burridge, Freelance Journalist